Written by: Dr. Akash Chandawarkar, Board Certified Plastic Surgeon, Mirror Plastic Surgery
Key Takeaways
- Juvéderm and Restylane are both FDA-approved hyaluronic acid fillers. The right choice depends on facial zone, tissue behavior, and injector expertise.
- Zone-specific selection matters: Restylane Kysse or Juvéderm Volbella for lips, Juvéderm Voluma or Restylane Lyft/Contour for cheeks, and Volbella or Restylane Eyelight for tear troughs.
- Longevity varies by area and product: lips typically last 9–12 months, nasolabial folds 12–18 months, and midface up to 24 months. MRI evidence shows some HA can persist far longer.
- High-risk zones such as the glabella, nasal tip, and tear troughs call for precise anatomical knowledge, conservative volumes, and reversible HA fillers to reduce vascular complications.
- Mirror Plastic Surgery uses physician-led, anatomy-first filler planning that focuses on natural results and safety instead of sheer volume.
Get A Personalized Filler Plan At Mirror Plastic Surgery
The Short Answer: Juvéderm Vs. Restylane
Both Juvéderm and Restylane are FDA-approved dermal fillers. Neither brand is universally better. The treatment area, the desired result, and the injector’s assessment of your anatomy determine which product fits your needs. Juvéderm gels are homogenous smooth gels, with the Hylacross formulations (Juvéderm Ultra and Ultra Plus) more hydrophilic than the Vycross products. Restylane gels tend to feel firmer and absorb less water, and that physical difference guides area-specific selection.
How To Decide Between Juvéderm And Restylane
The decision usually follows a simple five-step framework.
- Identify the facial zone you want to treat.
- Match the product’s physical properties to that zone’s tissue behavior.
- Confirm the product has an FDA-approved indication for that area.
- Plan for realistic longevity and maintenance.
- Confirm that filler is the right tool for your concern.
Discuss Your Filler Options With Dr. Akash
Key Background Before You Choose A Filler
Dermal fillers are cross-linked, or chemically bonded, to slow the body’s natural breakdown of the molecule and extend the visible effect. Dermal fillers are regulated by the FDA as Class III medical devices, the highest-risk device category, requiring premarket approval (PMA) rather than simple clearance, and each approved filler has a specific labeled indication tied to anatomic location and patient age.
An “FDA-approved indication” means the manufacturer ran a controlled clinical trial in a specific anatomical zone and proved safety and efficacy to the FDA’s standard. Using a product outside its approved indication is legal, but it changes the risk-benefit balance and calls for extra judgment.
A major safety advantage of HA fillers over biostimulatory options is reversibility. HA fillers can be dissolved with hyaluronidase if something goes wrong, whereas CaHA (Radiesse), PLLA (Sculptura), PMMA (Bellafill), and autologous fat cannot be reversed once placed.
The two product families differ in their cross-linking technology, and that difference, rather than branding, shapes where each product works best.
- Juvéderm (Allergan/AbbVie): The Hylacross family uses 100% high-molecular-weight HA, has higher water absorption and swelling, and typically lasts 6–12 months. The Vycross family uses 90% low-molecular-weight plus 10% high-molecular-weight HA cross-linking, creating a tighter polymer matrix with minimal swelling, and typically lasts 6–24 months by area.
- Restylane (Galderma): Uses XpresHAn Technology to produce soft, flexible gels that move naturally with facial expression, alongside NASHA-based firmer gels with higher G-prime for structural support.
Named products covered in this guide include Juvéderm Voluma XC, Vollure XC, and Volbella XC, plus Restylane Contour, Lyft, Refyne, Defyne, Kysse, and Eyelight, along with additional products such as Restylane-L and Juvéderm Ultra XC, Ultra Plus XC, and Volux XC.
How Treatment Planning Typically Works
A physician-led filler consultation focuses on anatomy, not on picking from a product menu. Before choosing between Juvéderm and Restylane, a qualified injector evaluates tissue thickness, skin quality, bone support, prior filler history, and movement patterns. Facial aging occurs at multiple levels at once: the skin thins and loses elasticity, the bony scaffold remodels, and soft tissue descends, so volume alone cannot fully correct advanced aging.
At Mirror Plastic Surgery, this assessment takes place in a concierge-style consultation that can last up to an hour. The evaluation runs from top to bottom instead of focusing on a single “problem spot.” Dr. Akash first works to restore your inherent facial characteristics, then considers volume augmentation. This sequence helps prevent the overfilled look that appears in many high-volume practices.
Plan Your Anatomy-First Consultation With Dr. Akash
Juvéderm Vs. Restylane By Treatment Area
Lip Fillers: Restylane Vs. Juvéderm
Lip tissue is highly mobile, thin, and vascular, so it benefits from a soft, flexible gel for superficial volume and a firmer gel for border support. Juvéderm Volbella XC is FDA-approved for lip augmentation and correction of perioral rhytids under PMA P110033/S018, with 61.8% of subjects maintaining fullness at Month 12.1 Restylane Kysse is a soft, flexible hyaluronic acid lip filler made by Galderma whose clinical study followed subjects for 12 months, with 60% of subjects showing at least a 1-point improvement in lip fullness at 12 months.1 Kysse uses XpresHAn Technology to create a soft, flexible gel that moves naturally with the lips, with results lasting up to 12 months in clinical trials.1 Restylane Defyne, a firmer XpresHAn gel with high lifting capacity, is used off-label by some providers for structural support and definition in the lips, such as the vermillion border, though it is not FDA-approved for lip augmentation. The choice depends on whether you want subtle hydration, sharper borders, or noticeable volume. For a deeper comparison, see Juvéderm Vs. Restylane For Lips: An Injector’s Guide.
Realistic longevity: lip products typically last 9–12 months because constant movement from talking, chewing, and expression speeds mechanical breakdown.1
Cheeks And Midface Fillers
The midface usually needs deep placement on periosteum for lift and projection, so it favors a firmer, cohesive gel with strong lifting capacity. Juvéderm Voluma XC is FDA-approved for deep injection (subcutaneous and/or supraperiosteal) for cheek augmentation under PMA P110033, with 85.6% of subjects responding at Month 6 and 67.1% maintaining response at Month 24, making it the only Juvéderm product with documented 2-year clinical persistence.1 Restylane Lyft and Restylane Contour are also appropriate for midface augmentation. Lyft is a higher G-prime, stiffer gel designed for cheek augmentation. A patient with strong bone support may need less structural product than someone with age-related fat pad descent, who often needs deeper support. For a detailed comparison of Voluma and Vollure, see Juvéderm Voluma Vs. Vollure: A Surgeon’s Guide To Choosing.
Tear Troughs And Under-Eye Fillers
The tear trough is one of the least forgiving injection zones. Skin is thin, subcutaneous tissue is minimal, and the area lies close to the orbital vasculature. Juvéderm Volbella XC is FDA-approved for deep subcutaneous or supraperiosteal injection to improve infraorbital hollows under PMA P110033/S053, with an 83.1% responder rate at Month 3 and 73.4% maintaining significant hollow improvement at Month 12.1 Restylane Eyelight is a NASHA Technology gel formulated for infraorbital hollowing that resists water absorption and minimizes swelling; in clinical studies, patients treated with Restylane Eyelight showed no Tyndall effect, though superficial injection can still cause bluish discoloration. The lateral orbital and tear trough-adjacent regions require conservative product selection because thin tissue, lymphatic sensitivity, edema risk, and vascular complexity narrow the safety margin. Under-eye treatment calls for a specific, low-hydrophilicity product, not leftover filler from another area.
Realistic longevity: hyaluronic acid tear trough fillers on average provide improvement for about 9 to 12 months, though some studies report longer durations.1
Nasolabial Fold Fillers
The nasolabial fold moves constantly, so a flexible, dynamic gel usually blends better with expression than a rigid one. Juvéderm Vollure XC is FDA-approved for correction of moderate to severe facial wrinkles and folds under PMA P110033/S020, with 59.4% of subjects maintaining response at Month 18.1 Restylane Refyne is an XpresHAn gel softer than Defyne, designed for moderate nasolabial folds with natural flexibility. Treating the fold alone, without restoring midface support, often looks unnatural because the fold frequently reflects midface descent rather than an isolated crease.
Realistic longevity: nasolabial fold filler longevity is product-specific. Standard hyaluronic acid fillers typically last about 6–12 months, while longer-lasting options such as calcium hydroxylapatite can last 12–18 months or more.
Chin And Jawline Fillers
Deep, firm product placed on periosteum can project the chin and sharpen the jawline. Juvéderm Voluma XC is approved for chin augmentation under PMA P110033/S047, with 57.6% of subjects responding at Month 12, though the FDA SSED notes that males and subjects aged 51.5 and older did not meet the 50% responder-rate threshold.1 Juvéderm Volux XC is approved for jawline definition under PMA P110033/S065, formulated with Allergan’s highest elasticity and cohesivity to mimic structural bone, lasting up to 12 months.1 Restylane Defyne and Lyft are used for structural lower-face support, including jawline contouring and chin augmentation, though their FDA-approved indications specifically cover chin augmentation for Defyne and cheek/midface augmentation for Lyft. Jowl formation often reflects structural change. Jowls do not arise from laxity alone, because descent or redistribution of cheek fat compartments and changes in surrounding soft-tissue relationships also contribute to lower-face aging. Adding volume directly into a jowl without correcting the underlying support rarely looks natural.
Realistic longevity: for hyaluronic acid fillers used in the chin and jawline, typical clinical effects last about 12–18 months, though results vary by product, placement, and individual factors.1
Product Comparison Table
The table below summarizes the products discussed above so you can quickly compare their main treatment areas, texture, and stated longevity.
| Product | Primary Treatment Area | Feel / Texture | Stated Longevity |
|---|---|---|---|
| Juvéderm Voluma XC | Cheeks, chin, temples | Firm, cohesive, high lift (Vycross) | Up to 24 months (cheeks), up to 12 months (chin) |
| Juvéderm Vollure XC | Nasolabial folds | Smooth, balanced firmness, low cohesivity (Vycross) | Up to 18 months |
| Juvéderm Volbella XC | Lips, tear troughs | Soft, low-swelling (Vycross) | Up to 12 months |
| Restylane Kysse | Lips, perioral lines | Soft, flexible (XpresHAn) | Up to 12 months |
| Restylane Contour | Cheeks, midface, temples | Soft, flexible, high lift (XpresHAn) | Up to 12 months (cheeks), up to 18 months (temples) |
| Restylane Lyft | Cheeks, midface, hands | Firm, high G-prime (NASHA) | Up to 12 months (cheeks), up to 6 months (folds, hands) |
| Restylane Refyne | Nasolabial folds | Flexible, natural (XpresHAn) | Up to 12 months |
| Restylane Defyne | Nasolabial folds, chin | Firmer, structural (XpresHAn) | Up to 12 months |
| Restylane Eyelight | Infraorbital hollows | Firm, supportive, low hydrophilicity | Up to 12 months, up to 18 months with optimal retreatment |
Compare These Options With Dr. Akash
How Long Does Each Filler Last?
Filler longevity does not come as a single number for each brand. It varies by product, treatment area, injection plane, patient metabolism, and total volume. Evidence-based guidance suggests maintenance every 9–12 months for lips, every 12–15 months for nasolabial folds, and every 18–24 months for midface cheek volume.1
The common claim that all HA fillers last “six months to a year” oversimplifies reality. Juvéderm Voluma in the cheeks has documented 2-year clinical persistence, while lip products stop at 12 months in their FDA trial designs because constant movement accelerates mechanical breakdown.1 Midface products last longer than lip products for anatomical reasons, not because one brand is superior. For a formula-by-formula breakdown, see How Long Does Juvéderm Last? A Formula-By-Formula Guide.
MRI data adds another layer. A 2024 MRI case series found HA filler detectable in all 33 evaluated mid-face patients with zero instances of complete dissipation over at least 2 years, and persistence up to 15 years in one patient. This finding suggests that re-injection schedules should account for residual product instead of assuming a blank slate.
Best Filler Approach For Older Skin
Aged skin shows epidermal thinning, flattening of the dermal–epidermal junction, declining fibroblast density, and dermal vascular atrophy. These changes alter how filler behaves in tissue. A product and technique that look great on a 35-year-old with good elasticity may appear heavy or unnatural on a 70-year-old with marked bone resorption and fat pad descent.
For a mature patient who is a good filler candidate, a firmer, deeper structural product placed on periosteum often matters more than superficial volume. Deep supraperiosteal placement near strong bony support zones can tolerate firmer, more elastic, cohesive HA products, especially in the lateral cheek, zygomatic, chin, or mandibular regions. Nobody is categorically “too old” for filler, but the indication must fit the anatomy, and in advanced aging, filler volume should not simply increase to compensate for poor surgical indications.
Create An Age-Appropriate Plan With Dr. Akash
Safest And Riskiest Places For Fillers
The main high-risk zones, in clinical order of concern, include:
- Glabella: Direct ophthalmic artery communication. A 2025 Ophthalmic Technology Assessment by the American Academy of Ophthalmology reviewed 19 articles and identified 198 cases of vision loss from filler; among the 196 cases with final vision reported, vision was unchanged in 70%, improved in 28%, and worsened in 2%.
- Nasal Tip And Alar Region: Filler injected into the dorsal nasal artery or lateral nasal artery can enter the ophthalmic circulation through arterial anastomoses and cause nasal tip skin necrosis or catastrophic vision loss, although such vision loss remains rare.
- Tear Troughs: In the tear trough, low-viscosity hyaluronic acid should be used, injected supraperiosteally in small volumes (for example, 0.1–0.2 mL per point), avoiding superficial placement to prevent the Tyndall effect and staying cautious around the infraorbital neurovascular bundle.
- Temples: The superficial temporal artery and its branches lie close to the skin surface in the temple. Incorrect placement of hyaluronic acid or dermal filler there can cause necrosis of the frontotemporal skin and the ipsilateral scalp, with superficial temporal artery embolization or compression suspected as the main mechanism.
- Nasolabial Folds: An anatomical study of 42 face-sides found anastomosis between the ophthalmic artery and the facial artery at the medial angle of the orbit in 60% of cases, and a separate study found the angular artery originated from the ophthalmic artery in 59.1% of hemi-faces, indicating that the nasolabial fold region carries a substantial risk of vascular connection to the ophthalmic circulation.
In a Netherlands-based study, the incidence of filler-associated vascular adverse events was estimated at 1:6558 (0.015%), with a credible range of 1:5300–1:8000, and the authors noted this figure may be underestimated because mild or misdiagnosed cases often go unreported. Physician-level anatomical training functions as a safety requirement in these zones, not just a credential preference. Higher-viscosity and higher-cohesivity HA fillers are more likely to worsen intravascular plugs than lower-viscosity fillers. Higher plunger pressures can further exacerbate these plugs. That is why product selection and injection technique must work together in high-risk areas.
How Long-Term Filler Use Affects Your Face
When filler is the only tool used, the tendency is to add more volume over time to keep pace with aging. Without periodic reassessment, patients can drift into “overfilled territory” that looks less natural than the aging it was meant to soften. Many patients now choose to dissolve accumulated filler and restart with a more conservative, anatomy-guided plan.
Why Some Patients Are Moving Away From Heavy Filler Use
The current cultural shift focuses on avoiding overfilling rather than rejecting fillers altogether. Excessive, poorly sequenced, or anatomically insensitive HA filler use may contribute to overfilled syndrome, distorted surface contours, facial heaviness, and cumulative aesthetic disharmony. These outcomes reflect inappropriate indication and poor technique rather than an unavoidable effect of HA as a material.
More patients now prioritize structural support and skin quality instead of sheer volume. Biostimulatory options such as Radiesse stimulate the body’s own collagen production and play a different role than HA fillers. HA fillers and biostimulators have complementary and overlapping roles. A patient with focal support deficiency and good skin quality may benefit from HA-based structural support, while a patient with diffuse dermal thinning, laxity, and poor tissue quality may benefit from biostimulation, and many patients need both strategies in stages or combination.
A physician who is not tied to a single product line can recommend less filler, or a different modality entirely, when that serves you better. Dr. Akash serves on advisory boards for multiple companies, including Merz Aesthetics and Tiger Aesthetics, and is not incentivized by any single manufacturer’s product volume.
Explore A Balanced Filler And Biostimulator Plan
Does Filler Ever Fully Leave Your Body?
HA fillers gradually break down through your own tissue enzymes (hyaluronidases) and metabolic processes. HA gels are biodegradable and temporary, with clinical effects usually lasting roughly 6–36 months depending on product, technique, and patient factors, although the process is not perfectly complete or predictable.
As noted earlier, the 2024 MRI case series found HA filler detectable in all 33 evaluated mid-face patients, with persistence up to 15 years in one patient. A separate 3D MRI study found that MRI-measured HA filler volume averaged 2.8 times the injected volume, with a mean MRI-measured volume of 12.26 mL versus a mean injected volume of 3.32 mL, a statistically significant difference (P = 0.006).
HA fillers can be dissolved with hyaluronidase, which remains their key safety advantage over biostimulatory fillers. In vitro, most HA fillers (for example, Belotero, Juvéderm, Restylane) reach significant degradation at 5 to 9 hours with 20 U/mL hyaluronidase. Degradation correlates positively with enzyme concentration and depends more on the filler’s cross-linking technology than on HA concentration or classic rheological parameters such as elastic modulus (G’). No universally accepted dosing protocol exists, and in vivo differences among fillers largely diminish beyond early time points. HA encased in a thick collagen fibrous capsule from long-standing injections shows reduced degradation because the capsule limits hyaluronidase access and confines enzymatic action to the surface.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
